Top Page
Covalon Technologies
(COV)
Covalon Technologies (COV) vs. iShares MSCI Canada ETF (EWC)
Covalon Technologies Business Overview & Revenue Model
Covalon Technologies Earnings Call Summary
Covalon Technologies Financial Statement Overview
| Breakdown | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 31.17M | 26.60M | 18.15M | 19.56M | 25.80M |
| Gross Profit | 18.93M | 14.36M | 7.49M | 9.70M | 12.49M |
| EBITDA | 3.14M | -3.49M | -8.11M | 1.54M | -6.63M |
| Net Income | 2.67M | -4.46M | -9.66M | 23.48M | -6.95M |
Balance Sheet | |||||
| Total Assets | 31.81M | 24.90M | 30.38M | 40.58M | 34.70M |
| Cash, Cash Equivalents and Short-Term Investments | 16.75M | 8.79M | 14.06M | 22.95M | 3.51M |
| Total Debt | 901.67K | 1.56M | 2.17M | 2.59M | 20.90M |
| Total Liabilities | 4.30M | 6.11M | 6.15M | 7.21M | 25.59M |
| Stockholders Equity | 27.50M | 18.79M | 24.23M | 33.37M | 9.11M |
Cash Flow | |||||
| Free Cash Flow | 3.06M | -4.50M | -9.08M | 443.71K | -4.40M |
| Operating Cash Flow | 3.47M | -3.18M | -7.99M | 621.37K | -4.03M |
| Investing Cash Flow | -281.63K | -81.02K | -843.02K | -278.53K | -370.41K |
| Financing Cash Flow | 4.97M | -2.16M | -2.19M | -8.25M | -1.75M |
Covalon Technologies Technical Analysis
Covalon Technologies Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | C$69.09M | 17.91 | 14.51% | ― | 28.97% | ― | |
60 Neutral | C$34.31M | 24.14 | -1.13% | ― | -9.54% | -105.12% | |
51 Neutral | $7.46B | -0.25 | -46.00% | 2.25% | 22.77% | -2.14% | |
43 Neutral | C$129.45M | ― | -244.84% | ― | ― | 2.33% | |
43 Neutral | C$52.32M | ― | ― | -33.66% | -48.89% | ||
33 Underperform | C$64.05M | ― | 248.46% | ― | ― | 49.34% | |
33 Underperform | C$90.47M | ― | 685.26% | ― | ― | -31.12% |
Covalon Technologies Corporate Events
Covalon Technologies announced it will release its third-quarter fiscal 2025 financial results on August 21, 2025, followed by a conference call and webcast to discuss the results. This announcement is significant for stakeholders as it provides insights into the company’s financial health and strategic direction, potentially impacting its market positioning and investor confidence.
Covalon Technologies Ltd. has announced a conference call to discuss its third quarter fiscal 2025 financial results, scheduled for August 21, 2025. This announcement reflects Covalon’s commitment to transparency and engagement with stakeholders, providing an opportunity for investors and analysts to gain insights into the company’s financial performance and strategic direction.
Covalon Technologies Ltd. announced it will release its third quarter fiscal 2025 financial results on August 21, 2025, followed by a conference call and webcast to discuss these results. This announcement is significant for stakeholders as it provides an opportunity to engage with company management and gain insights into Covalon’s financial performance and strategic direction.
Covalon Technologies Ltd. reported a strong fiscal second quarter for 2025, marking its fifth consecutive quarter of positive earnings. The company achieved a 21% increase in year-to-date revenue and a 57% rise in adjusted EBITDA. Key achievements include a major distribution agreement with Paul Hartmann USA and significant growth in its U.S. Vascular Access and Surgical Consumables sales channel, which saw a 46% increase year-to-date. Covalon’s strategic focus on market development and its North American-centric manufacturing strategy have positioned it well in the current global trade environment, with no tariff-related costs. The company is also exploring merger and acquisition opportunities to further enhance shareholder value.
Covalon Technologies Ltd. has announced promising results from a clinical study of its VALGuard® Vascular Access Line Guard, aimed at reducing Central Line-Associated Blood Stream Infections. The study’s findings will be presented at two prestigious scientific meetings and are advancing towards publication in an academic journal, highlighting the product’s potential impact on infection prevention in healthcare settings.
Covalon Technologies Ltd. has announced promising results from a clinical study on its VALGuard® Vascular Access Line Guard, which will be presented at two prestigious scientific meetings and is advancing towards publication in an academic journal. The study highlights VALGuard®’s effectiveness in reducing Central Line-Associated Blood Stream Infections, a significant concern in healthcare, and underscores its adoption by major hospitals in the United States as part of infection prevention programs. This development could enhance Covalon’s industry positioning and impact patient care positively.
Covalon Technologies Ltd. announced it will release its second quarter fiscal 2025 financial results on May 28, 2025, followed by a conference call and webcast to discuss the results. This announcement is significant as it provides stakeholders with insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and investor relations.
Covalon Technologies has engaged Origin Merchant Partners to explore strategic opportunities aimed at enhancing shareholder value, including potential joint ventures, partnerships, and a NASDAQ listing. The company aims to accelerate product adoption and unlock inherent value, citing significant growth in its Advanced Wound Care and Vascular Access segments in the U.S. market.
Covalon Technologies Ltd. has announced the promotion of Kim Crooks to Chief Operating Officer and her appointment to the Board of Directors. This move is expected to strengthen the company’s leadership, as Crooks has been pivotal in enhancing operational efficiency since rejoining the company. Her promotion and board appointment are anticipated to align Covalon’s operations with its strategic objectives, potentially impacting its market positioning positively.